Enzo Biochem Story

<div class='circular--portrait' style='background:#FF0000;color: #F8F8FF;font-size:4em;'>EB</div>
ENZ -- USA Stock  

USD 3.47  0.11  3.27%

Enzo Biochem Accounts Payable Turnover is fairly stable at the moment as compared to the past year. Enzo Biochem reported Accounts Payable Turnover of 11.06 in 2020. Accrued Expenses Turnover is likely to rise to 10.27 in 2021, whereas Net Income Per Employee is likely to drop (58.6 K) in 2021. Enzo Biochem is scheduled to announce its earnings today. As some conservatives are trying to avoid healthcare space, we'll break down Enzo Biochem a little further and explain its current market possibilities. We will analyze why it could be a much better year for Enzo Biochem shareholders. We currently estimate Enzo Biochem as undervalued. The real value is approaching 4.04 per share.
Published over a month ago
View all stories for Enzo Biochem | View All Stories
How strong are Enzo Biochem (NYSE:ENZ) basic indicators given the current rise?
We provide trade advice to complement the prevailing expert consensus on Enzo Biochem. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Enzo Biochem income statement, its balance sheet, and the statement of cash flows. Potential Enzo Biochem investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Enzo Biochem investors may use each financial statement separately, they are all related. The changes in Enzo Biochem's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Enzo Biochem's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Enzo Biochem fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Enzo Biochem performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Enzo Biochem shares is the value that is considered the true value of the share. If the intrinsic value Enzo Biochem is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Enzo Biochem.
Please read more on our fundamental analysis page.

How important is Enzo Biochem's Liquidity

Enzo Biochem financial leverage refers to using borrowed capital as a funding source to finance Enzo Biochem ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Enzo Biochem financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Enzo Biochem's total debt and its cash.

How Enzo Biochem utilizes its cash?

To perform a cash flow analysis of Enzo Biochem, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Enzo Biochem is receiving and how much cash it distributes out in a given period. The Enzo Biochem cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Enzo Biochem Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Enzo Biochem reported Net Cash Flow from Operations of (19.76 Million) in 2020

Enzo Biochem Gross Profit

Enzo Biochem Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Enzo Biochem previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Enzo Biochem Gross Profit growth over the last 10 years.
Please check Gross Profit in more details.

Sale by Harbert Management Corp of 100000 shares of Enzo Biochem

Legal trades by Enzo Biochem insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Enzo Biochem insider trading alert for sale of common stock by Harbert Management Corp, the corporate stakeholder, on 17th of March 2021. This event was filed by Enzo Biochem Inc with SEC on 2021-03-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Institutional investors typically avoid acquiring a high percentage of Enzo Biochem stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Enzo Biochem is distributed among investors.

Ownership Allocation

Enzo Biochem holds a total of fourty-seven million nine hundred thousand outstanding shares. Over half of Enzo Biochem outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Enzo Biochem. Please watch out for any change in the institutional holdings of Enzo Biochem as this could mean something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Retail Investors
Retail Investors30.64
 2018 2019 2020 2021 (projected)
Revenues USD81.17 M76.02 M68.42 M76.41 M
Revenues81.17 M76.02 M68.42 M76.41 M

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Enzo Biochem has an asset utilization ratio of 75.54 percent. This suggests that the company is making $0.76 for each dollar of assets. An increasing asset utilization means that Enzo Biochem is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
77.6 M
Assets Non Current
33.9 M
Current Assets77.58 Million65.29
Assets Non Current33.85 Million28.49
Goodwill7.38 Million6.21

Our take on Enzo Biochem small slide

Enzo Biochem current potential upside rises over 5.81. Enzo Biochem shows above-average downside volatility for the selected time horizon. We advise investors to inspect Enzo Biochem further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Enzo Biochem future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Enzo Biochem's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Enzo Biochem's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Conclusion on Enzo Biochem

While other entities in the diagnostics & research industry are either recovering or due for a correction, Enzo Biochem may not be performing as strong as the other in terms of long-term growth potentials. All things considered, as of the 15th of March 2021, our analysis shows that Enzo Biochem follows the market closely. The company is undervalued and projects quite high probability of distress for the next 2 years. Our primary 30 days buy vs. sell advice on the company is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Enzo Biochem. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com